| Generic name | Lomustine |
| Pronunciation | loh-MUS-teen |
| Brand name(s), other common name(s) | CeeNU®, CCNU |
| Drug type | DNA-damaging agent |
| How the drug is given | By mouth |
Indications and Usage
Lomustine is FDA approved as a secondary therapy in combination with other drugs to treat people with Hodgkin lymphoma who relapse while being treated with primary therapy or who fail to respond to primary therapy.
Side effects needing medical attention
Fever, chills or sore throat; unusual bleeding or bruising; infection; confusion; slurred speech; sores in mouth and on lips; swelling of feet or lower legs; unusual decrease in urination; unusual tiredness or weakness; yellowing of eyes and skin; cough or shortness of breath.
Side effects needing medical attention after stopping this medication
Fever, chills or sore throat; unusual bleeding or bruising; loss of appetite; nausea and vomiting (usually lasts less than 24 hours); darkening of skin; rash and itching or pinhead-sized red spots on skin; black, tarry stools; blood in urine or stools; cough or hoarseness; lower back or side pain; painful or difficult urination.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.